This is a preview of subscription content, log in via an institution to check access.
Notes
2018 US dollars
Reference
Kashiwa M, et al. Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan. Clinical Therapeutics : 26 Apr 2019. Available from: URL: http://doi.org/10.1016/j.clinthera.2019.03.011
Rights and permissions
About this article
Cite this article
Prophylactic aprepitant cost effective but not fosaprepitant. PharmacoEcon Outcomes News 828, 28 (2019). https://doi.org/10.1007/s40274-019-5902-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5902-x